Clinical Trials Logo
  1. Home
  2. Bronchiolitis Obliterans
  3. NCT04098445
  4. Details
NCT04098445 Clinical Trial

TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients

Bronchiolitis Obliterans Clinical Trial

Official title:
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04098445
Other study ID # 2019-0001C
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 8, 2021
Est. completion date September 2036

Study information
Verified date January 2024
Source Children's Hospital Medical Center, Cincinnati
Contact Stephanie Edwards, BSN, RN
Phone 513-636-9292
Email StephanieL.Edwards@cchmc.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary morbidity affects as many as 25% of children receiving transplant. Early pulmonary injury includes diffuse alveolar hemorrhage (DAH), thrombotic microangiopathy (TMA) interstitial pneumonitis (IPS) and infection, while later, bronchiolitis obliterans is a complication of chronic GVHD associated with severe morbidity and mortality. Improved diagnosis and treatment of pulmonary complications are urgently needed as survival after HSCT improves, and as HSCT is increasingly used for non-malignant disorders such as sickle cell disease. Currently, there are large and important gaps in the investigator's knowledge regarding incidence, etiology and optimal treatment of pulmonary complications. Moreover, young children unable to perform spirometry are often diagnosed late, and strategies for monitoring therapeutic response are limited. This is a prospective multi-institutional cohort study in pediatric patients undergoing allogeneic (alloHSCT) or autologous hematopoietic stem cell transplantation (autoHSCT). Assembly of a large prospective uniformly screened cohort of children receiving HSCT, together with collection of biological samples, will be an effective strategy to identify mechanisms of lung injury, test novel diagnostic strategies for earlier diagnosis, and novel treatments to reduce morbidity and mortality from lung injury after transplant.

Recruitment information / eligibility
Status Recruiting
Enrollment 2000
Est. completion date September 2036
Est. primary completion date September 2026
Accepts healthy volunteers No
Gender All
Age group N/A to 24 Years
Eligibility Inclusion Criteria: - Subjects = 24 years of age undergoing allogeneic or autologous HSCT. Exclusion Criteria: - Subjects over 24 years of age.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United States Dana-Farber Cancer Institute/Boston Children's Hospital Boston Massachusetts
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Baylor College of Medicine/Texas Children'S Hospital Houston Texas
United States University of Minnesota Minneapolis Minnesota
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States University of California San Francisco San Francisco California
United States Fred Hutchinson Cancer Center Seattle Washington
United States Seattle Children'S Hospital Seattle Washington

Sponsors (1)
Lead Sponsor Collaborator
Children's Hospital Medical Center, Cincinnati

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Incidence of Lung Injury after HSCT Participants will be assessed for lung injury at 24 months after HSCT 24 months after HSCT
See also
  Status Clinical Trial Phase
Recruiting NCT03603899 - Hp129 Xenon Imaging and BOS in Lung Transplantation Phase 1/Phase 2
Completed NCT02441413 - Transplant Optimization Using Functional Imaging (TROFI) N/A
Recruiting NCT02543073 - MSC for Treatment of Interstitial Lung Disease After Allo-HSCT Phase 1/Phase 2
Terminated NCT01432080 - Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant Phase 2
Recruiting NCT00163696 - Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease N/A
Completed NCT00029328 - Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation Phase 1/Phase 2
Terminated NCT01163786 - A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD Phase 2
Recruiting NCT02627833 - Lung Function, LCI, Bronchial Inflammation and Epigenetics of Patients With BO N/A
Completed NCT01212406 - Vitamin D in Bronchiolitis Obliterans Syndrome Phase 4
Completed NCT01211509 - Montelukast in Bronchiolitis Obliterans Syndrome Phase 4
Completed NCT00701922 - Surveillance Study of Viral Infections Following Lung Transplantation N/A
Completed NCT00141726 - Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant Phase 2
Recruiting NCT05922761 - BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) Phase 2
Recruiting NCT05881538 - High Intensity Intervallic Training in Children With Bronchiolitis Obliterans N/A
Terminated NCT04655508 - Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation Phase 3
Withdrawn NCT02109237 - Sleep Disorders in Bronchiolitis Obliterans Syndrome 2&3 N/A
Completed NCT01327248 - Clinical Status and Bronchial Inflammation in Patients With Bronchiolitis Obliterans N/A
Recruiting NCT05932316 - Evaluating Bronchodilator Response in Patients With Bronchiectasis N/A
Active, not recruiting NCT03656926 - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) Phase 3
Terminated NCT01327625 - Efficacy Study of Azithromycin-based Therapy for Bronchiolitis Obliterans N/A